Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,146

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

Open access
Lalu, Manoj M., McIntyre, Lauralyn, Pugliese, Christina, Fergusson, Dean, Winston, Brent W., Marshall, John C., Granton, John, Stewart, Duncan J., Canadian Critical Care Trials Group·2012·PLoS ONE
DOI 10.1371/journal.pone.0047559
Open this paper in CoChat — free account

Abstract

BACKGROUND: Mesenchymal stromal cells (MSCs, "adult stem cells") have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. METHODS AND FINDINGS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever. CONCLUSIONS: Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0047559

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 54

  1. AJ Friedenstein, 1974, Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo, Transplantation, 17, 331, 10.1097/00007890-197404000-00001 · DOI · Paper page
  2. AI Caplan, 2009, Why are MSCs therapeutic? New data: new insight, J Pathol, 217, 318, 10.1002/path.2469 · DOI · Paper page
  3. MA Matthay, 2010, Mesenchymal stem cells for acute lung injury: preclinical evidence, Crit Care Med, 38, S569, 10.1097/CCM.0b013e3181f1ff1d · DOI · Paper page
  4. SH Mei, 2007, Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1, PLoS Med, 4, e269, 10.1371/journal.pmed.0040269 · DOI · Paper page
  5. SHJ Mei, 2010, Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis, American Journal of Respiratory and Critical Care Medicine, 182, 1047, 10.1164/rccm.201001-0010OC · DOI · Paper page
  6. AJ Boyle, 2010, Mesenchymal stem cell therapy for cardiac repair, Methods Mol Biol, 660, 65, 10.1007/978-1-60761-705-1_5 · DOI
  7. DJ Prockop, 2010, Defining the risks of mesenchymal stromal cell therapy, Cytotherapy, 12, 576, 10.3109/14653249.2010.507330 · DOI · Paper page
  8. JP Ioannidis, 2004, The value of meta-analysis in rheumatology research, Autoimmun Rev, 3 Suppl 1, S57
  9. (2005) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5, The Cochrane Library. In: Higgins JPT, Green S, editors. Chichester, UK: John Wiley & Sons, Ltd.
  10. S Chen, 2006, Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery, J Invasive Cardiol, 18, 552
  11. SL Chen, 2004, Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction, Chin Med J (Engl), 117, 1443
  12. JM Hare, 2009, A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, J Am Coll Cardiol, 54, 2277, 10.1016/j.jacc.2009.06.055 · DOI · Paper page
  13. JS Lee, 2010, A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke, Stem Cells, 28, 1099, 10.1002/stem.430 · DOI · Paper page
  14. PH Lee, 2008, Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy, Clin Pharmacol Ther, 83, 723, 10.1038/sj.clpt.6100386 · DOI · Paper page
  15. H Ning, 2008, The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study, Leukemia, 22, 593, 10.1038/sj.leu.2405090 · DOI · Paper page
  16. JA Wang, 2006, [A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy], Zhonghua Xin Xue Guan Bing Za Zhi, 34, 107
  17. ZW Xie, 2007, Curative effect of autologous mesenchymal stem cell transplantation on spinal cord injury. [Chinese], Journal of Clinical Rehabilitative Tissue Engineering Research, 11, 1277
  18. F Baron, 2010, Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning, Biol Blood Marrow Transplant, 16, 838, 10.1016/j.bbmt.2010.01.011 · DOI · Paper page
  19. R Gonzalo-Daganzo, 2009, Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults, Cytotherapy, 11, 278, 10.1080/14653240902807018 · DOI
  20. P Kebriaei, 2009, Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease, Biol Blood Marrow Transplant, 15, 804, 10.1016/j.bbmt.2008.03.012 · DOI · Paper page
  21. ON Koc, 2002, Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH), Bone Marrow Transplant, 30, 215, 10.1038/sj.bmt.1703650 · DOI · Paper page
  22. HM Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use, Bone Marrow Transplant, 16, 557
  23. HM Lazarus, 2005, Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients, Biol Blood Marrow Transplant, 11, 389, 10.1016/j.bbmt.2005.02.001 · DOI · Paper page
  24. L Liu, 2006, Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1+CD31-CD34- mesenchymal stem cells: feasibility and safety from monkey to human, Stem Cells Dev, 15, 349, 10.1089/scd.2006.15.349 · DOI
  25. M Mohyeddin-Bonab, 2007, Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction, Arch Iran Med, 10, 467
  26. O Ringden, 2006, Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, Transplantation, 81, 1390, 10.1097/01.tp.0000214462.63943.14 · DOI · Paper page
  27. AV Vanikar, 2011, Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness, Int Urol Nephrol, 43, 225, 10.1007/s11255-009-9659-1 · DOI
  28. N Arima, 2010, Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study, Cytotherapy, 12, 265, 10.3109/14653240903390795 · DOI
  29. B Fang, 2007, Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease, Transplant Proc, 39, 3358, 10.1016/j.transproceed.2007.08.103 · DOI · Paper page
  30. O Honmou, 2011, Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke, Brain, 134, 1790, 10.1093/brain/awr063 · DOI · Paper page
  31. D Karussis, 2010, Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis, Arch Neurol, 67, 1187, 10.1001/archneurol.2010.248 · DOI · Paper page
  32. K Le Blanc, 2008, Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study, Lancet, 371, 1579, 10.1016/S0140-6736(08)60690-X · DOI · Paper page
  33. J Liang, 2010, Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study, Ann Rheum Dis, 69, 1423, 10.1136/ard.2009.123463 · DOI · Paper page
  34. J Liang, 2011, Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease, Gut
  35. N Meuleman, 2009, Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study, Stem Cells Dev, 18, 1247, 10.1089/scd.2009.0029 · DOI
  36. M Mohamadnejad, 2007, Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis, Arch Iran Med, 10, 459
  37. O Ringden, 2007, Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon, Leukemia, 21, 2271, 10.1038/sj.leu.2404833 · DOI · Paper page
  38. L Sun, 2009, Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans, Stem Cells, 27, 1421, 10.1002/stem.68 · DOI · Paper page
  39. L Sun, 2010, Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus, Arthritis Rheum, 62, 2467, 10.1002/art.27548 · DOI · Paper page
  40. D Wang, 2011, Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis, Ann Rheum Dis, 70, 1285, 10.1136/ard.2010.141804 · DOI
  41. JY Weng, 2010, Mesenchymal stem cell as salvage treatment for refractory chronic GVHD, Bone Marrow Transplant, 45, 1732, 10.1038/bmt.2010.195 · DOI · Paper page
  42. Z Yang, 2010, A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery, Cardiovasc Ther, 28, 380, 10.1111/j.1755-5922.2009.00116.x · doi:10.1111/j.1755-5922.2009.00116.x
  43. X Zhang, 2010, Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases, Int J Lab Hematol, 32, 256, 10.1111/j.1751-553X.2009.01181.x · doi:10.1111/j.1751-553x.2009.01181.x
  44. ZX Zhang, 2008, A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury, Cytotherapy, 10, 134, 10.1080/14653240701883061 · DOI
  45. A Uccelli, 2008, Mesenchymal stem cells in health and disease, Nat Rev Immunol, 8, 726, 10.1038/nri2395 · DOI · Paper page
  46. P Frere, 2006, Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen, Bone Marrow Transplant, 37, 411, 10.1038/sj.bmt.1705255 · DOI
  47. JE Hendrickson, 2009, Noninfectious serious hazards of transfusion, Anesth Analg, 108, 759, 10.1213/ane.0b013e3181930a6e · DOI · Paper page
  48. K Le Blanc, 2003, HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells, Exp Hematol, 31, 890, 10.1016/S0301-472X(03)00110-3 · DOI · Paper page
  49. A Shahdadfar, 2005, In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability, Stem Cells, 23, 1357, 10.1634/stemcells.2005-0094 · DOI · Paper page
  50. JL Spees, 2004, Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy, Mol Ther, 9, 747, 10.1016/j.ymthe.2004.02.012 · DOI · Paper page
  51. R Syme, 2004, The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity, Biol Blood Marrow Transplant, 10, 135, 10.1016/j.bbmt.2003.09.016 · doi:10.1016/j.bbmt.2003.09.016
  52. P Windrum, 2005, Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres, Bone Marrow Transplant, 36, 601, 10.1038/sj.bmt.1705100 · DOI · Paper page
  53. BB Chin, 2003, 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction, Nucl Med Commun, 24, 1149, 10.1097/00006231-200311000-00005 · DOI · Paper page
  54. DA Fergusson, 2008, The future of clinical trials evaluating blood substitutes, JAMA, 299, 2324, 10.1001/jama.299.19.jed80027 · DOI

Cited by

See all 1,146

Metadata

Authors
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J., & Canadian Critical Care Trials Group
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-10-25
Volume
7
Issue
10
Pages
e47559
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0047559
OpenAlex
W2031790029
Cited by
1,146
References
3
FWCI
6.82
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. https://app.cochat.ai/papers/10.1371/journal.pone.0047559
The paper
Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J., & Canadian Critical Care Trials Group. (2012). Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE. https://doi.org/10.1371/journal.pone.0047559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.